Celladon Corporation (CLDN) 1.15 $CLDN
Celladon Sets Date for Special Meeting of Stockholders
GlobeNewswire - Wed Feb 10, 3:57PM CST
Celladon Corporation (Nasdaq:CLDN) announced today it has set a date for a special meeting of its stockholders to vote on matters related to the proposed merger with Eiger BioPharmaceuticals, Inc.
CLDN: 1.15 (-0.02)
Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO
GlobeNewswire - Fri Nov 20, 6:05AM CST
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today announced the appointment of Paul B. Cleveland to chief executive officer (CEO) and to the Board of Directors effective December 9. He also will serve as principal financial officer of Avalanche on an interim basis. Mr. Cleveland, previously the chief executive officer of Celladon Corporation, brings more than 20 years of leadership experience to Avalanche, including management and operational experience across the biotechnology industry. This includes positions at multiple public biotechnology companies, including CEO, president, chief financial officer and Board member as well as chief operating officer at a venture capital firm. Subsequent to December 9, Hans P. Hull who has been serving as interim CEO of Avalanche since July, will return to his previous role of senior vice president of business operations.
CLDN: 1.15 (-0.02), AAVL: 4.14 (-0.18)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Eiger BioPharmaceuticals, Inc. - CLDN
ACCESSWIRE - Thu Nov 19, 4:36PM CST
NEW YORK, NY / ACCESSWIRE / November 19, 2015 / The following statement is being issued by Levi & Korsinsky, LLP:
CLDN: 1.15 (-0.02)
CELLADON ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Launches an Investigation into the Proposed Merger of Celladon Corporation; Are Celladon Shareholders Getting a Fair Deal?
BusinessWire - Thu Nov 19, 8:45AM CST
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Celladon Corporation (NASDAQ: CLDN) breached their fiduciary duties in connection with the proposed merger of the Company with Eiger BioPharmaceuticals, Inc.
CLDN: 1.15 (-0.02)
72-Hour Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of August 31, 2015 Lead Plaintiff Deadline in the Class Action Lawsuit Against Celladon Corp.
BusinessWire - Fri Aug 28, 7:58PM CDT
Law Offices of Howard G. Smith reminds investors of the August 31,2015 lead plaintiff deadline in the class action lawsuit filed on behalf of a class comprising purchasers of the securities of Celladon Corporation ("Celladon" or the "Company"
(NASDAQ:CLDN), who purchased shares between July 7, 2014 and June 25, 2015, inclusive (the "Class Period" . Investors with losses of over $100,000 are encouraged to contact Howard G. Smith, Esq. to discuss their legal rights.
CLDN: 1.15 (-0.02)
August 31 Deadline in Lawsuit for Investors in Celladon Corp (NASDAQ:CLDN) Shares Announced by Shareholders Foundation
GlobeNewswire - Tue Aug 25, 8:55AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed against Celladon Corp over alleged Securities Laws Violations and that a deadline is upcoming on August 31, 2015 for investors with a substantial investment in (NASDAQ:CLDN) shares between July 7, 2014 and June 25, 2015.
CLDN: 1.15 (-0.02)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Celladon Corporation of Class Action Lawsuit and Upcoming Deadline - CLDN
GlobeNewswire - Mon Aug 24, 7:00AM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Celladon Corporation ("Celladon" or the "Company" (NASDAQ:CLDN) and certain of its officers. The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities who purchased Celladon securities between July 7, 2014 and June 25, 2015 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
CLDN: 1.15 (-0.02)
SECURITIES ALERT: The Rosen Law Firm Reminds Celladon Corporation Investors of the Important August 31, 2015 Deadline in the Class Action -- CLDN
GlobeNewswire - Fri Aug 21, 5:04PM CDT
The Rosen Law Firm, a global investor rights firm, reminds purchasers of Celladon Corporation (NASDAQ:CLDN) common stock from July 7, 2014 through June 25, 2015, all dates inclusive, of the important August 31, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Celladon investors under the federal securities laws.
CLDN: 1.15 (-0.02)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Celladon Corporation and Lead Plaintiff Deadline August 31, 2015
GlobeNewswire - Thu Aug 20, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the Southern District of California on behalf of those who purchased shares of Celladon Corporation ("Celladon" or the "Company" (Nasdaq:CLDN), during the period between July 7, 2014 and June 25, 2015 inclusive. (the "Class Period" .
CLDN: 1.15 (-0.02)
GPM Announces the Filing of a Securities Class Action on Behalf of Celladon Corp. Investors
BusinessWire - Wed Aug 19, 3:48PM CDT
Glancy Prongay & Murray LLP ("GPM" announces the filing of a class action lawsuit on behalf of investors of Celladon Corporation ("Celladon" or the "Company" (NASDAQ:CLDN), who purchased shares between July 7, 2014 and June 25, 2015, inclusive (the "Class Period" . Celladon investors have until August 31, 2015 to file a motion to serve as lead plaintiff in the class action.
CLDN: 1.15 (-0.02)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of August 31, 2015
BusinessWire - Mon Aug 17, 1:51PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CLDN: 1.15 (-0.02)
Hypertension - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hypertension
M2 - Fri Aug 14, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gn56xn/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: - Introduction - Hypertension Overview - Therapeutics Development - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - Hypertension - Therapeutics Assessment - Drug Profiles - Hypertension - Recent Pipeline Updates - Hypertension - Dormant Projects - Hypertension - Discontinued Products - Hypertension - Product Development Milestones Companies Mentioned - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Ahn-Gook Pharmaceutical Co., Ltd. - Alnylam Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Angion Biomedica Corp. - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Bio-inRen - Biocon Limited - Biolab Sanus Farmaceutica Ltda. - BioLineRx, Ltd. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Cellceutix Corporation - Celsion Corporation - Chong Kun Dang Pharmaceutical Corp. - CJ CheilJedang Corp. - Conatus Pharmaceuticals Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dong-A Socio Group - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/gn...pertension
CYTK: 12.07 (-0.02), CNAT: 1.81 (-0.07), CLDN: 1.15 (-0.02), LLY: 77.75 (-0.02), CLSN: 1.24 (-0.01), ASND: 18.44 (+0.34), ABBV: 64.10 (-0.06), ANAC: 99.06 (-0.14), ARNA: 1.55 (-0.02)
Celladon Reports Second Quarter 2015 Financial Results
GlobeNewswire - Tue Aug 11, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), today announced financial results for the quarter ended June 30, 2015 and recent corporate updates.
CLDN: 1.15 (-0.02)
CELLADON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Celladon Corporation To Contact The Firm
PR Newswire - Tue Aug 11, 3:00PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Celladon Corporation ("Celladon" or the "Company" (NASDAQ:CLDN) of the August 31, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Celladon and certain officers. The lawsuit has been filed in the United States District Court for the Southern District of California, on behalf of a class consisting of all persons or entities who purchased Celladon securities between July 7, 2014 and June 25, 2015 (the "Class Period" .
CLDN: 1.15 (-0.02)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Celladon Corporation and a Lead Plaintiff Deadline of August 31, 2015 - CLDN
GlobeNewswire - Mon Aug 10, 10:18AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Celladon Corporation (NASDAQ:CLDN) securities between July 7, 2014 and June 25, 2015.
CLDN: 1.15 (-0.02)
Global Arteriovenous Fistula Clinical Trials Review, H1, 2015 - Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals or Companies
M2 - Wed Aug 05, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kcqk26/arteriovenous) has announced the addition of the "Arteriovenous Fistula Global Clinical Trials Review, H1, 2015" report to their offering. Arteriovenous Fistula Global Clinical Trials Review, H1, 2015 provides data on the Arteriovenous Fistula clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Arteriovenous Fistula. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Arteriovenous Fistula. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Shire Plc - Proteon Therapeutics, Inc. - CYATHUS EXQUIRERE Pharmaforschungs GmbH - Celladon Corporation Clinical Trial Overview of Top Institutes / Government - California Institute of Renal Research - Capital Medical University - City Hospitals Sunderland NHS Foundation Trust - Department of Health, UK - Duke University - Emory University - Englewood Hospital and Medical Center - Japan Interventional Radiology in Oncology Study Group - National Cheng-Kung University Hospital - NHS Greater Glasgow and Clyde For more information visit http://www.researchandmarkets.com/research/kc...eriovenous
SHPG: 187.18 (-3.04), CLDN: 1.15 (-0.02), PRTO: 8.82 (-0.90)
SECURITIES ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Celladon Corporation -- CLDN
GlobeNewswire - Fri Jul 31, 5:10PM CDT
The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Celladon Corporation (NASDAQ:CLDN) securities from July 7, 2014 through June 25, 2015, all dates inclusive. The lawsuit seeks to recover damages for Celladon investors under the federal securities laws.
CLDN: 1.15 (-0.02)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of August 31, 2015 - CLDN
PR Newswire - Thu Jul 30, 1:03PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CLDN: 1.15 (-0.02)
Morgan & Morgan Reminds Investors That Class Action Lawsuits Have Been Filed Against Celladon Corporation -- CLDN
GlobeNewswire - Thu Jul 30, 12:31PM CDT
Morgan & Morgan reminds investors that securities class actions have been filed in the United States District Court for the Southern District of California on behalf of those who purchased shares of Celladon Corp. ("Celladon" or the "Company" (Nasdaq:CLDN), during the period between July 7, 2014 and June 25, 2015, inclusive (the "Class Period" .
CLDN: 1.15 (-0.02)
Lifshitz & Miller Law Firm Announces Investigation of Celladon Corporation, Edison International, Inc., Louisiana Bancorp, Inc., Navient Corp., On Deck Capital, Inc., Thoratec, and Vivint Solar
PR Newswire - Fri Jul 24, 6:47PM CDT
Celladon Corporation
ONDK: 6.33 (-0.06), THOR: 63.50 (+0.05), CLDN: 1.15 (-0.02), VSLR: 3.18 (+0.03), LABC: 24.36 (+0.08), NAVI: 14.38 (-0.03), EIX: 72.72 (+0.76)
Celladon Sets Date for Special Meeting of Stockholders
GlobeNewswire - Wed Feb 10, 3:57PM CST
Celladon Corporation (Nasdaq:CLDN) announced today it has set a date for a special meeting of its stockholders to vote on matters related to the proposed merger with Eiger BioPharmaceuticals, Inc.
CLDN: 1.15 (-0.02)
Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO
GlobeNewswire - Fri Nov 20, 6:05AM CST
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today announced the appointment of Paul B. Cleveland to chief executive officer (CEO) and to the Board of Directors effective December 9. He also will serve as principal financial officer of Avalanche on an interim basis. Mr. Cleveland, previously the chief executive officer of Celladon Corporation, brings more than 20 years of leadership experience to Avalanche, including management and operational experience across the biotechnology industry. This includes positions at multiple public biotechnology companies, including CEO, president, chief financial officer and Board member as well as chief operating officer at a venture capital firm. Subsequent to December 9, Hans P. Hull who has been serving as interim CEO of Avalanche since July, will return to his previous role of senior vice president of business operations.
CLDN: 1.15 (-0.02), AAVL: 4.14 (-0.18)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Eiger BioPharmaceuticals, Inc. - CLDN
ACCESSWIRE - Thu Nov 19, 4:36PM CST
NEW YORK, NY / ACCESSWIRE / November 19, 2015 / The following statement is being issued by Levi & Korsinsky, LLP:
CLDN: 1.15 (-0.02)
CELLADON ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Launches an Investigation into the Proposed Merger of Celladon Corporation; Are Celladon Shareholders Getting a Fair Deal?
BusinessWire - Thu Nov 19, 8:45AM CST
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Celladon Corporation (NASDAQ: CLDN) breached their fiduciary duties in connection with the proposed merger of the Company with Eiger BioPharmaceuticals, Inc.
CLDN: 1.15 (-0.02)
72-Hour Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of August 31, 2015 Lead Plaintiff Deadline in the Class Action Lawsuit Against Celladon Corp.
BusinessWire - Fri Aug 28, 7:58PM CDT
Law Offices of Howard G. Smith reminds investors of the August 31,2015 lead plaintiff deadline in the class action lawsuit filed on behalf of a class comprising purchasers of the securities of Celladon Corporation ("Celladon" or the "Company"
(NASDAQ:CLDN), who purchased shares between July 7, 2014 and June 25, 2015, inclusive (the "Class Period" . Investors with losses of over $100,000 are encouraged to contact Howard G. Smith, Esq. to discuss their legal rights. CLDN: 1.15 (-0.02)
August 31 Deadline in Lawsuit for Investors in Celladon Corp (NASDAQ:CLDN) Shares Announced by Shareholders Foundation
GlobeNewswire - Tue Aug 25, 8:55AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed against Celladon Corp over alleged Securities Laws Violations and that a deadline is upcoming on August 31, 2015 for investors with a substantial investment in (NASDAQ:CLDN) shares between July 7, 2014 and June 25, 2015.
CLDN: 1.15 (-0.02)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Celladon Corporation of Class Action Lawsuit and Upcoming Deadline - CLDN
GlobeNewswire - Mon Aug 24, 7:00AM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Celladon Corporation ("Celladon" or the "Company"
(NASDAQ:CLDN) and certain of its officers. The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities who purchased Celladon securities between July 7, 2014 and June 25, 2015 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . CLDN: 1.15 (-0.02)
SECURITIES ALERT: The Rosen Law Firm Reminds Celladon Corporation Investors of the Important August 31, 2015 Deadline in the Class Action -- CLDN
GlobeNewswire - Fri Aug 21, 5:04PM CDT
The Rosen Law Firm, a global investor rights firm, reminds purchasers of Celladon Corporation (NASDAQ:CLDN) common stock from July 7, 2014 through June 25, 2015, all dates inclusive, of the important August 31, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Celladon investors under the federal securities laws.
CLDN: 1.15 (-0.02)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Celladon Corporation and Lead Plaintiff Deadline August 31, 2015
GlobeNewswire - Thu Aug 20, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the Southern District of California on behalf of those who purchased shares of Celladon Corporation ("Celladon" or the "Company"
(Nasdaq:CLDN), during the period between July 7, 2014 and June 25, 2015 inclusive. (the "Class Period" . CLDN: 1.15 (-0.02)
GPM Announces the Filing of a Securities Class Action on Behalf of Celladon Corp. Investors
BusinessWire - Wed Aug 19, 3:48PM CDT
Glancy Prongay & Murray LLP ("GPM"
announces the filing of a class action lawsuit on behalf of investors of Celladon Corporation ("Celladon" or the "Company" (NASDAQ:CLDN), who purchased shares between July 7, 2014 and June 25, 2015, inclusive (the "Class Period" . Celladon investors have until August 31, 2015 to file a motion to serve as lead plaintiff in the class action. CLDN: 1.15 (-0.02)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of August 31, 2015
BusinessWire - Mon Aug 17, 1:51PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CLDN: 1.15 (-0.02)
Hypertension - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hypertension
M2 - Fri Aug 14, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gn56xn/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: - Introduction - Hypertension Overview - Therapeutics Development - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - Hypertension - Therapeutics Assessment - Drug Profiles - Hypertension - Recent Pipeline Updates - Hypertension - Dormant Projects - Hypertension - Discontinued Products - Hypertension - Product Development Milestones Companies Mentioned - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Ahn-Gook Pharmaceutical Co., Ltd. - Alnylam Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Angion Biomedica Corp. - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Bio-inRen - Biocon Limited - Biolab Sanus Farmaceutica Ltda. - BioLineRx, Ltd. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Cellceutix Corporation - Celsion Corporation - Chong Kun Dang Pharmaceutical Corp. - CJ CheilJedang Corp. - Conatus Pharmaceuticals Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dong-A Socio Group - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/gn...pertension
CYTK: 12.07 (-0.02), CNAT: 1.81 (-0.07), CLDN: 1.15 (-0.02), LLY: 77.75 (-0.02), CLSN: 1.24 (-0.01), ASND: 18.44 (+0.34), ABBV: 64.10 (-0.06), ANAC: 99.06 (-0.14), ARNA: 1.55 (-0.02)
Celladon Reports Second Quarter 2015 Financial Results
GlobeNewswire - Tue Aug 11, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), today announced financial results for the quarter ended June 30, 2015 and recent corporate updates.
CLDN: 1.15 (-0.02)
CELLADON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Celladon Corporation To Contact The Firm
PR Newswire - Tue Aug 11, 3:00PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Celladon Corporation ("Celladon" or the "Company"
(NASDAQ:CLDN) of the August 31, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Celladon and certain officers. The lawsuit has been filed in the United States District Court for the Southern District of California, on behalf of a class consisting of all persons or entities who purchased Celladon securities between July 7, 2014 and June 25, 2015 (the "Class Period" . CLDN: 1.15 (-0.02)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Celladon Corporation and a Lead Plaintiff Deadline of August 31, 2015 - CLDN
GlobeNewswire - Mon Aug 10, 10:18AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Celladon Corporation (NASDAQ:CLDN) securities between July 7, 2014 and June 25, 2015.
CLDN: 1.15 (-0.02)
Global Arteriovenous Fistula Clinical Trials Review, H1, 2015 - Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals or Companies
M2 - Wed Aug 05, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kcqk26/arteriovenous) has announced the addition of the "Arteriovenous Fistula Global Clinical Trials Review, H1, 2015" report to their offering. Arteriovenous Fistula Global Clinical Trials Review, H1, 2015 provides data on the Arteriovenous Fistula clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Arteriovenous Fistula. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Arteriovenous Fistula. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Shire Plc - Proteon Therapeutics, Inc. - CYATHUS EXQUIRERE Pharmaforschungs GmbH - Celladon Corporation Clinical Trial Overview of Top Institutes / Government - California Institute of Renal Research - Capital Medical University - City Hospitals Sunderland NHS Foundation Trust - Department of Health, UK - Duke University - Emory University - Englewood Hospital and Medical Center - Japan Interventional Radiology in Oncology Study Group - National Cheng-Kung University Hospital - NHS Greater Glasgow and Clyde For more information visit http://www.researchandmarkets.com/research/kc...eriovenous
SHPG: 187.18 (-3.04), CLDN: 1.15 (-0.02), PRTO: 8.82 (-0.90)
SECURITIES ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Celladon Corporation -- CLDN
GlobeNewswire - Fri Jul 31, 5:10PM CDT
The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Celladon Corporation (NASDAQ:CLDN) securities from July 7, 2014 through June 25, 2015, all dates inclusive. The lawsuit seeks to recover damages for Celladon investors under the federal securities laws.
CLDN: 1.15 (-0.02)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of August 31, 2015 - CLDN
PR Newswire - Thu Jul 30, 1:03PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CLDN: 1.15 (-0.02)
Morgan & Morgan Reminds Investors That Class Action Lawsuits Have Been Filed Against Celladon Corporation -- CLDN
GlobeNewswire - Thu Jul 30, 12:31PM CDT
Morgan & Morgan reminds investors that securities class actions have been filed in the United States District Court for the Southern District of California on behalf of those who purchased shares of Celladon Corp. ("Celladon" or the "Company"
(Nasdaq:CLDN), during the period between July 7, 2014 and June 25, 2015, inclusive (the "Class Period" . CLDN: 1.15 (-0.02)
Lifshitz & Miller Law Firm Announces Investigation of Celladon Corporation, Edison International, Inc., Louisiana Bancorp, Inc., Navient Corp., On Deck Capital, Inc., Thoratec, and Vivint Solar
PR Newswire - Fri Jul 24, 6:47PM CDT
Celladon Corporation
ONDK: 6.33 (-0.06), THOR: 63.50 (+0.05), CLDN: 1.15 (-0.02), VSLR: 3.18 (+0.03), LABC: 24.36 (+0.08), NAVI: 14.38 (-0.03), EIX: 72.72 (+0.76)
